Uterine Cancer Drugs Market 2026 | Global Analysis, Latest Industry Trends, Recasts Revenue Growth At Global & Country Level, Size, Share, Demand, Challenges And Sub-Segments From 2021 To 2026

SEATTLE, April 01, 2021, (PHARMIWEB) — Uterine cancer is a type of cancer that begins in the uterus. It is the most common cancer of the female reproductive system. There are two types of uterine cancer: endometrial cancer and uterine sarcoma. Abnormal growth of inner linings of uterus leads to endometrial cancer. This type of cancer is often curable. Uterine sarcoma progresses in the muscle and supporting tissues of the uterus. This type of cancer is rare. According to National Cancer Institute, Megestrol Acetate was the only drug approved by U.S. Food and Drug Administration (FDA) for the treatment of endometrial cancer till March 2016. Endometrial biopsy, colposcopy or Pap smear screening test is used to diagnose endometrial cancer and uterine sarcoma.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1745

Increasing R&D of targeted cancer therapies to augment the market growth

Increasing funding for R&D in cancer and targeted cancer drugs research and favorable insurance policies for the treatment of various types of cancer are expected to propel growth of the global uterine cancer drugs market. For instance, in 2015, National Cancer Institute invested around US$ 4,480 million on cancer research, which included uterine cancer, cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukemia, and ovarian cancer. Moreover, according to the American Cancer Society, in 2014, around US$ 87.8 billion was invested for R&D in cancer in the U.S., of which around 44% was paid by private insurance companies.

Widely recommended therapy for the treatment of uterine sarcomas is chemotherapy. However, chemotherapy is not effective in certain types of uterine sarcoma. The therapy is often conducted in the earlier stages of uterine sarcoma. Dacarbazine (DTIC), Docetaxel (Taxotere), Liposomal doxorubicin (Doxil), Paclitaxel (Taxol), and Epirubicin (Ellence) are some of the chemotherapy drugs used in the treatment of uterine sarcoma.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/2PQdv8X

Major institutes and market players are focused on conducting clinical trials for potential therapies against endometrial cancer and uterine sarcoma. This in turn is expected to boost growth of the market. For instance, according to the U.S. National Library of Medicine, August 2017 Clinical Trials Database, Memorial Sloan Kettering Cancer Center: a cancer treatment and research institute in New York is focused on conducting two clinical trials for uterine cancer, which includes Phase II study of Nivolumab immunotherapy for the treatment of recurrent or persistent uterine cancer and phase I trial for Selinexor (KPT-330) with Paclitaxel and Carboplatin for the treatment of advanced ovarian and endometrial cancers.

High prevalence of uterine cancer and focus of government and private organizations on R&D of potent therapies for endometrial cancer and uterine sarcoma is also expected to boost growth of the uterine cancer drugs market over the forecast period. For instance, according to the American Cancer Society, January 2018, around 63,230 new cases of uterine cancer are estimated to be diagnosed in the U.S. and around 11,350 women are expected to die from uterine cancer in 2018. These estimates include both endometrial cancers and uterine sarcomas and in most of the times, up to 8% of uterine body cancers are sarcomas. According to the same source, endometrial cancer majorly affects post-menopausal women, with the average age of 60 years. According to the Cancer Research UK, in 2015, uterine cancer is the fourth most common cancer among the women’s in the U.K. with around 9,000 new cases in 2015. Furthermore, uterine cancer accounted for 5% of all new cancer cases in females in the UK for the same year (2015).

North America is expected to hold dominant position in the market during the forecast period

North America is expected to account for the largest market share during the forecast period, owing to high prevalence endometrial cancer in the region. For instance, according to the International Agency for Research on Cancer: 2014 data findings, published by World Cancer Research Fund International, in January 2015, around 53% of the endometrial cancer cases were reported in developed economies, which includes U.S., Luxemburg, Norway, Poland, and among others. Moreover, according to the same source incidence of endometrial cancer was fond to be highest in North America and Europe and the lowest incidence in Africa and Asia Pacific. According to the data published in Journal of the National Cancer Institute in April 2018, North America and Eastern and Northern Europe witnessed the highest rate of endometrial cancer incidence and lowest rate were reported in middle-income countries including South Africa and India.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1745

According to World Health Organization (WHO) 2018 data findings, cervical cancer is the fourth most frequent type of cancer in women, which accounted for an estimated 530,000 new cases in 2012, representing 7.9% of all female cancers. Furthermore, according to WHO: 2018, around 90% the 270,000 deaths from cervical cancer in 2015 are occurred in low- and middle-income countries. Furthermore, the prevalence of endometrial cancer is higher in developed economics such as the in North America and the Europe, owing to changing lifestyles of women in these countries. The prevalence of uterine cancer is more common in women aged 50 years and above. These factors are expected to contribute to growth of the markets in North America and Europe, followed by Asia Pacific.

Uterine Cancer Drugs Market Competitive Landscape

Major players operating in the uterine cancer drugs market include Par Pharmaceutical Companies, Inc., United Biotech Pvt Ltd., Elder Pharmaceuticals Ltd., Merck & Company, Inc., and Actiza Pharmaceutical Private Limited.

To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/1745

Uterine Cancer Drugs Market Taxonomy:

By Indication:

• Endometrial Cancer
• Uterine Sarcoma

By Product Type:

• Megestrol Acetate
• Dacarbazine (DTIC)
• Docetaxel (Taxotere)
• Gemcitabine (Gemzar)
• Epirubicin (Ellence)
• Paclitaxel (Taxol)
• Temozolomide (Temodar)
• Others

By Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Table of Content

Global Uterine Cancer Drugs Market Research Report
Section 1: Global Uterine Cancer Drugs Industry Overview
Section 2: Global Economic Impact on Uterine Cancer Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Uterine Cancer Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Uterine Cancer Drugs Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737